Mark Hurwitz is an Oncology physician affiliated with Westchester Medical Center. OpenAlex indexes 238 publications with 5,177 citations (h-index 37); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Woods Rd
Valhalla, NY 105951530
Telephone
914-493-8561Provider last certified this registry record 10 Jan 2022.
Clinical trials
- Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
Sponsor: Boston Scientific Corporation
- Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Sponsor: Radiation Therapy Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20251 payment
- GT Medical Technologies, IncProgram year20253 payments
- Zap Surgical Systems, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
100%alpha-Adrenergic Blocker100%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Journal of Clinical Oncology
2020 - Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Prostate Cancer and Prostatic Diseases
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Stephan Mayer, MD
Westchester Medical Center
William Frishman, MD
Westchester Medical Center
Srihari Naidu, MD
Westchester Medical Center
Delong Liu, MD, PhD
Westchester Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”